

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:

T12A100%  
seen=2,000

 • 

I13V100%  
seen=2,000

 • 

K14R100%  
seen=2,000

 • 

G16E100%  
seen=2,000

 • 

R41K100%  
seen=4,370

 • 

L63S100%  
seen=3,000

 • 

I64V100%  
seen=3,000

 • 

E65D100%  
seen=3,000

 • 

I72V100%  
seen=2,000

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

No drug resistance mutations were found for PI.

NRTI Mutations:

K219KQ100%  
seen=1,620

NNRTI Mutations:

K103KN100%  
seen=1,000

 N: 75% N: 20% • 

V179T100%  
seen=2,000

 • 

P225H100%  
seen=2,000

RT Other Mutations:

V35T100%  
seen=1,000

 • 

T39G100%  
seen=1,000

 • 

V60I100%  
seen=1,000

 • 

K104KR100%  
seen=1,000

 N: 80% N: 10% • 

D121DHY100%  
seen=1,000

 D: 100% Y: 20% H: 10% • 

K122E100%  
seen=1,000

 • 

D123E100%  
seen=1,000

 • 

S162C100%  
seen=2,000

 • 

K173KE100%  
seen=2,000

 N: 70% D: 20% • 

D177E100%  
seen=2,000

 • 

T200Q100%  
seen=2,000

 • 

Q207G100%  
seen=1,000

 • 

R211K100%  
seen=1,000

 • 

V245T100%  
seen=200

 • 

D250E100%  
seen=200

 • 

A554NS100%  
seen=100

 N: 70% D: 20% • 

V559I100%  
seen=200

Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Potential Low-Level Resistance
stavudine (D4T)	Potential Low-Level Resistance
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Intermediate Resistance
efavirenz (EFV)	High-Level Resistance
etravirine (ETR)	Susceptible
nevirapine (NVP)	High-Level Resistance
rilpivirine (RPV)	Susceptible

RT comments

NRTI

- K219E/Q/N/R are accessory TAMs that usually occur in combination with multiple other TAMs.

NNRTI

- K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
- V179T is a rare non-polymorphic mutation occasionally selected in persons receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility.
- P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.

Drug resistance mutation scores of NRTI:

Download CSV

Rule	ABC	AZT	D4T	DDI	FTC	3TC	TDF
K219KQ	5	10	10	5	0	0	5

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR	EFV	ETR	NVP	RPV
K103KN + P225H	10	0	0	0	0
P225H	20	45	0	45	0
K103KN	0	60	0	60	0
Total	30	105	0	105	0

INSTI Major Mutations:None

INSTI Accessory Mutations:[T97A](#) 1%  
from 100%

IN Other Mutations:[S17N](#) 100%  
from 95% • [M50V](#) 99%  
from 90% • [I72V](#) 100%  
from 85% • [T112V](#) 100%  
from 50% • [I113V](#) 99%  
from 50% • [S119T](#) 100%  
from 90% • [T124A](#) 99%  
from 50% • [T125A](#) 100%  
from 50% • [V201I](#) 100%  
from 90% • [L234I](#) 100%  
from 90% • [D253E](#) 99%  
from 70% • [N254G](#) 100%  
from 70% • [D279G](#) 100%  
from 70% • [S283G](#) 99%  
from 70%

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Potential Low-Level Resistance
raltegravir (RAL)	Potential Low-Level Resistance

IN comments

Accessory

- T97A** is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs.

Drug resistance mutation scores of INSTI:

Download CSV

Rule	BIC ↕	CAB ↕	DTG ↕	EVG ↕	RAL ↕
<a href="#">T97A</a>	0	0	0	10	10